Advisory Services Network’s Arcutis Biotherapeutics ARQT Stock Holding History

Advisory Services Network’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19	Closed	-$448	–	2306
2026 Q1	$448	Buy	+19	New	+$485	﹤0.01%	4447
2025 Q4	–	Sell	-19	Closed	-$358	–	1943
2025 Q3	$358	Buy	+19	New	+$300	﹤0.01%	4109
2023 Q2	–	Sell	-435	Closed	-$4.79K	–	1562
2023 Q1	$4.79K	Hold	435	–	–	﹤0.01%	3168
2022 Q4	$6.44K	Buy	+435	New	+$7.6K	﹤0.01%	3035

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Advisory Services Network's ARQT Position: Q2 2026 in Review

Advisory Services Network sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 19 shares — an estimated $448 sold.

Advisory Services Network first reported a position in ARQT in Q4 2022 and held it in 4 quarters. The position peaked at $6.44K in Q4 2022. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Advisory Services Network reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 19 Arcutis Biotherapeutics shares in Q2 2026, an estimated $448.
Advisory Services Network first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 4 quarters.
Advisory Services Network's Arcutis Biotherapeutics position peaked at $6.44K in Q4 2022.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.